




## **Appendix**

**This appendix was part of the submitted manuscript and has been peer reviewed.  
It is posted as supplied by the authors.**


Appendix to: Wright F, Hapgood G, Loganathan A, et al. Relative survival of patients with lymphoma in Queensland according to histological subtype. *Med J Aust* 2018; 209: 177-183. doi: 10.5694/mja17.00937.

**Figure 1. Five-year relative survival (with 95% confidence intervals) of each lymphoma subtype, 1993–2012, by socio-economic status quintiles**



DLBCL = diffuse large B-cell lymphoma; PTCL = peripheral T-cell lymphoma. Socio-economic status (Index of Relative Socio-economic Disadvantage, IRSD): quintile 1, most disadvantaged; quintile 5, least disadvantaged.

**Figure 2. Five-year relative survival (with 95% confidence intervals) of each lymphoma subtype, 1993–2012, by location of residence**



DLBCL = diffuse large B-cell lymphoma; PTCL = peripheral T-cell lymphoma.

**Table. Relative survival, by lymphoma subtype: univariate analysis**

	Lymphoma histology subtype									
	Diffuse large B-cell lymphoma		Follicular lymphoma		Highly aggressive lymphoma		Hodgkin lymphoma		Peripheral T-cell lymphoma	
	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
<b>Sex</b>										
Female	1		1		1		1		1	
Male	1.07 (0.97–1.18)	0.18	1.14 (0.97–1.34)	0.10	0.70 (0.46–1.08)	0.11	1.48 (1.15–1.92)	0.003	1.13 (0.91–1.41)	0.25
<b>Residence</b>										
Urban	1		1		1		1		1	
Rural	1.07 (0.97–1.19)	0.18	1.28 (1.09–1.51)	0.003	0.78 (0.50–1.22)	0.28	1.30 (1.00–1.70)	0.05	1.25 (1.01–1.56)	0.042
<b>Socio-economic status</b>										
Quintile 5 (least disadvantaged)	1		1		1		1		1	
Quintiles 2–4 (middle)	1.19 (1.03–1.37)	0.019	1.23 (0.97–1.56)	0.09	1.06 (0.60–1.86)	0.84	1.44 (1.00–2.08)	0.048	1.26 (0.93–1.69)	0.14
Quintile 1 (most disadvantaged)	1.24 (1.04–1.48)	0.017	1.58 (1.20–2.07)	0.001	1.19 (0.59–2.38)	0.62	1.81 (1.17–2.79)	0.008	1.18 (0.82–1.70)	0.38
<b>Age group (years)</b>										
15–24	0.51 (0.30–0.88)	0.015	NA	NA	0.29 (0.14–0.62)	0.001	0.14 (0.08–0.25)	< 0.001	0.12 (0.03–0.50)	0.003
25–34	0.50 (0.32–0.77)	0.002	0.49 (0.22–1.11)	0.09	0.37 (0.16–0.86)	0.020	0.11 (0.06–0.22)	< 0.001	0.53 (0.28–1.00)	0.05
35–44	0.90 (0.69–1.18)	0.46	0.67 (0.43–1.02)	0.06	0.37 (0.15–0.91)	0.030	0.24 (0.13–0.43)	< 0.001	0.86 (0.54–1.38)	0.53
45–54	0.92 (0.74–1.14)	0.44	0.61 (0.44–0.85)	0.004	0.50 (0.22–1.15)	0.10	0.34 (0.19–0.61)	< 0.001	0.79 (0.53–1.18)	0.25
55–64	1		1		1		1		1	
65–74	1.73 (1.47–2.04)	< 0.001	2.15 (1.70–2.72)	< 0.001	1.35 (0.68–2.68)	0.39	2.14 (1.45–3.15)	< 0.001	2.15 (1.58–2.93)	< 0.001
75–84	3.40 (2.91–3.98)	< 0.001	3.76 (2.97–4.75)	< 0.001	1.66 (0.81–3.40)	0.17	3.18 (2.09–4.83)	< 0.001	2.58 (1.89–3.51)	< 0.001
85 or older	6.09 (5.05–7.36)	< 0.001	7.62 (5.50–10.55)	< 0.001	1.58 (0.57–4.38)	0.38	23.88 (14.01–40.68)	< 0.001	4.93 (3.07–7.90)	< 0.001
<b>Rituximab era*</b>										
No	1		1		1		1		1	
Yes	0.70 (0.64–0.78)	< 0.001	0.50 (0.41–0.61)	< 0.001	NA		NA		NA	
<b>Year group</b>										
1993–1997	1		1		1		1		1	
1998–2002	1.01 (0.88–1.17)	0.88	0.64 (0.52–0.78)	< 0.001	0.43 (0.25–0.76)	0.004	0.93 (0.64–1.36)	0.72	1.25 (0.91–1.71)	0.17
2003–2007	0.64 (0.55–0.74)	< 0.001	0.44 (0.36–0.54)	< 0.001	0.25 (0.14–0.46)	< 0.001	0.79 (0.55–1.14)	0.21	1.14 (0.84–1.55)	0.41
2008–2012	0.64 (0.55–0.74)	< 0.001	0.29 (0.23–0.38)	< 0.001	0.38 (0.22–0.66)	0.001	1.20 (0.84–1.70)	0.32	1.42 (1.05–1.91)	0.022

HR = hazard ratio; NA = not applicable. \* For diffuse large B-cell lymphoma: from July 2003 for patients aged 60 years or more, from April 2005 for those under 60; for patients with untreated advanced stage follicular lymphoma: from December 2006.